Multimodal Neuromonitoring at the ICU

University Hospital, Antwerp50 enrolled

Overview

Neurocritical care has become a distinct discipline within the field of intensive care medicine with a major focus on the treatment of patients with acute damage to the most complex organ of the human body, the brain. The main indications for acute neurocritical care concern aneurysmal Subarachnoid Hemorrhage (SAH) and severe Traumatic Brain Injury (TBI). These disease entities form a major health and socioeconomic problem as they afflict young patients and the rate of death and disability is high. The pathology and treatment of these patients is heterogeneous and complex. Despite advances in basic neuroscience which have increased our understanding of processes in the injured brain, approaches to management are largely unfocused and adhere to the concept of a 'one pill for everybody' approach. Novel monitoring technology and new neuroimaging techniques now offer opportunities for advancing the care for these patients to a more individualized targeted management. In the period of 2010-2014, a prospective trial was conducted in the Antwerp University Hospital, including 50 patients with either SAH or TBI, who underwent extensive monitoring, known as "Individualized targeted management in neurocritical care". In NEMO-RETRO, the investigators want to answer proposed and new research questions in retrospective analyses, using current insights and methodologies. Objectives: 1. Cerebral blood flow monitoring 1. Investigate the effect of changes in therapy (nature/intensity) on Cerebral Blood Flow (CBF) measured by thermal diffusion flowmetry and Transcranial Doppler (TCD) 2. Determine the added value of continuous CBF monitoring for the early detection of vasospasm and ischaemia 2. Brain tissue oxygen tension 1. Investigate the effect of changes in therapy (nature/intensity) on cerebral oxygenation as measured by Brain Tissue Oxygen Tension (PTiO2) 2. Investigate the relation between PTiO2 and hemodynamic parameters such as CBF, CPP, and ICP 3. Systemic effects of brain specific therapy 1. Investigate the effects of brain-targeted therapy on cardiac output and lung function 2. Determine the relation of CBF to cardiac output, in particular following triple H therapy 4. Neuroimaging 1. Accurately document structural brain damage following TBI and SAH 2. Document vasospasm and quantify flow and perfusion 3. Quantify the degree of secondary ischaemic damage to the brain 4. Differentiate swelling from edema 5. Train and validate models to interpret neuroimaging 5. Outcome 1. Assess global functional outcome at 6 months post-injury 2. Assess health-related quality of life at 6 months after injury 6. Integrated approach analysis 1. Describe the effects of brain-targeted therapy on cerebral and systemic parameters 2. Define the added value of extended multimodality monitoring and advanced neuroimaging to detect vasospasm and secondary ischaemic damage, defined by markers of neuronal injury and cell death 3. Develop recommendations for individualized targeted management

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

This study is based on the 50 patients recruited for the original study. For TBI: Inclusion Criteria: * male or female patients aged 18 to 70 years, inclusive * sustained head injury within the previous 24 hours * TBI diagnosed by history, clinical examination with a GCS of 12 or less * evidence of TBI confirmed by abnormalities on CT scan * clinical indication to monitor ICP * informed consent is obtained from the patient or from a legally acceptable representative Exclusion Criteria: * life expectancy of less than 24 hours as determined by the investigator * any spinal cord injury * coma suspected to be primarily due to causes other than head injury, such as drug or alcohol overdose * clinically significant or active gastro-intestinal, renal, hepatic, endocrine or CNS disease or chronic condition (e.g.psychiatric disorder) that can be ascertained at the time of admission and could affect functional outcome * respiratory/hemodynamic instability, refractory to treatment and precluding transport for neuroimaging studies * pregnancy * special exclusion criteria for MRI, such as non-removable metals, artificial joints, electronic devices (pacemaker, pumps etc.) * informed consent is obtained from a legally acceptable representative, prior to any study related activity For aneurysmal subarachnoid hemorrhage: Inclusion Criteria: * male or female patients aged 18 to 70 years, inclusive * ruptured aneurysm, demonstrated by CT angiography or DSA * onset of SAH clinical symptoms within the preceding 72 hours * World Federation of Neurosurgery (WFNS) grade III-IV and grade V patients, who improve within 24 hours after ventriculostomy * indication for ICP monitoring or CSF drainage * informed consent is obtained from the patient or a legally acceptable representative Exclusion Criteria: * non-aneurysmal subarachnoid hemorrhage * admission in a clinical state with extremely poor prognosis (e.g. wide, non-reactive pupils for more than 1 hour) * significant coagulation disturbances (thrombocytes \< 80 per mL, partial thromboplastin time \> 45 sec, INR \> 1.5) * cytostatic therapy in patients with malignant disease * pregnancy * special exclusion criteria for MRI, such as non-removable metals, artificial joints, electronic devices (pacemaker, pumps etc.) * respiratory and/or hemodynamic instability precluding

Outcomes

Primary Outcomes

Number of participants with a favourable neurological outcome

Glasgow Outcome Scale - Extended (GOSE; 1 = Dead, 8 = Upper good recovery)

Time frame: From enrollment to the end of follow-up at 6 months

Secondary Outcomes

Change from baseline in abnormalities on neuroimaging through CT, MRI or XA

Change based on evolution of bleeding areas, ischemic areas, edema

Time frame: From enrollment to the end of the study at 6 months